CN104857365A - Drug combination for curing senile macular oedema - Google Patents
Drug combination for curing senile macular oedema Download PDFInfo
- Publication number
- CN104857365A CN104857365A CN201510205634.5A CN201510205634A CN104857365A CN 104857365 A CN104857365 A CN 104857365A CN 201510205634 A CN201510205634 A CN 201510205634A CN 104857365 A CN104857365 A CN 104857365A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- pharmaceutical composition
- age
- radix
- crude drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a drug combination for curing the senile macular oedema. The drug combination for curing the senile macular oedema is effective and free of side effects. Heating and reflux condensation are conducted on stragalus membranaceus, Chinese yam, cinnamon, ormosia, poria cocos, ampelopsis japonica, largehead atractylodes, white pharbitis nil, saffron crocus, sanguis draconis, sophora flavescens and coix seed with ethanol water for 2-4 times for drug liquid mixing, and the drug combination can be obtained after filtrate condensing and drying.
Description
Technical field
The present invention relates to pharmaceutical formulating art, particularly relate to a kind of pharmaceutical composition for the treatment of age-related macular edema.
Background technology
Summary of the invention
The technical problem to be solved in the present invention be to provide a kind of can effectively, the pharmaceutical composition for the treatment of age-related macular edema that has no side effect.
For reaching above-mentioned purpose, a kind of pharmaceutical composition for the treatment of age-related macular edema of the present invention, comprises following crude drug and is prepared from: the Radix Astragali, Rhizoma Dioscoreae, Cortex Cinnamomi, Semen Phaseoli, Poria, Radix Ampelopsis, the Rhizoma Atractylodis Macrocephalae, lead a cow in vain, Stigma Croci, Sanguis Draxonis, Radix Sophorae Flavescentis, Cortex Moutan, Semen Coicis.
Wherein said crude drug consumption is: Radix Astragali 10-20 weight portion, Rhizoma Dioscoreae 5-10 weight portion, Cortex Cinnamomi 3-5 weight portion, Semen Phaseoli 1-3 weight portion, Poria 5-10 weight portion, Radix Ampelopsis 2-5 weight portion, Rhizoma Atractylodis Macrocephalae 3-5 weight portion, to lead a cow 1-3 weight portion, Stigma Croci 3-5 weight portion, Sanguis Draxonis 1-3 weight portion, Radix Sophorae Flavescentis 3-5 weight portion in vain, Cortex Moutan 3-5 weight portion, Semen Coicis 5-10 weight portion.
Wherein said crude drug consumption is: the Radix Astragali 15 weight portion, Rhizoma Dioscoreae 8 weight portion, Cortex Cinnamomi 4 weight portion, Semen Phaseoli 2 weight portion, Poria 8 weight portion, Radix Ampelopsis 3 weight portion, the Rhizoma Atractylodis Macrocephalae 4 weight portion, to lead a cow 2 weight portions, Stigma Croci 4 weight portion, Sanguis Draxonis 2 weight portion, Radix Sophorae Flavescentis 4 weight portion in vain, Cortex Moutan 4 weight portion, Semen Coicis 8 weight portion.
Wherein merge medicinal liquid by after described crude drug ethanol water heating-condensing backflow 2-4 time, be drying to obtain after filtrate is concentrated, described ethanol water concentration is 70-95%, and consumption is 5-8 times of crude drug gross weight.
Wherein said reflow's cycle is 3 times, and each return time is 3 hours.
The invention difference from existing technology is that the present invention achieves following technique effect:
The present invention adopts natural Chinese medicines composition, without any side effects; Cooperatively interacted by each crude drug, mutually auxiliary formation can conditioning viscera, Yin Yang balancing, soothing liver-QI gas, promoting blood circulation, change blood stasis, smooth circulation, toxin expelling element, molten mottle, increase-volume face, has good effect for treating age-related macular edema.
Detailed description of the invention
Below in conjunction with embodiment, to above-mentioned being described in more detail with other technical characteristic and advantage of the present invention.
Embodiment 1
Choose following crude drug: the Radix Astragali 15 weight portion, Rhizoma Dioscoreae 8 weight portion, Cortex Cinnamomi 4 weight portion, Semen Phaseoli 2 weight portion, Poria 8 weight portion, Radix Ampelopsis 3 weight portion, the Rhizoma Atractylodis Macrocephalae 4 weight portion, to lead a cow 2 weight portions, Stigma Croci 4 weight portion, Sanguis Draxonis 2 weight portion, Radix Sophorae Flavescentis 4 weight portion in vain, Cortex Moutan 4 weight portion, Semen Coicis 8 weight portion.
Ethanol water 350 weight portion heating-condensing by medicinal for above-mentioned raw materials 95% merges medicinal liquid after refluxing 4 times each 3 hours, is drying to obtain after filtrate is concentrated, adopts common method to be made into capsule or oral liquid.
Embodiment 2
Choose following crude drug: the Radix Astragali 10 weight portion, Rhizoma Dioscoreae 5 weight portion, Cortex Cinnamomi 5 weight portion, Semen Phaseoli 1 weight portion, Poria 5 weight portion, Radix Ampelopsis 5 weight portion, the Rhizoma Atractylodis Macrocephalae 5 weight portion, to lead a cow 1 weight portion, Stigma Croci 3 weight portion, Sanguis Draxonis 1 weight portion, Radix Sophorae Flavescentis 5 weight portion in vain, Cortex Moutan 3 weight portion, Semen Coicis 10 weight portion;
Ethanol water 450 weight portion heating-condensing by medicinal for above-mentioned raw materials 80% merges medicinal liquid after refluxing 2 times each 3 hours, is drying to obtain pharmaceutical composition, its tabletting is made tablet after filtrate is concentrated.
Embodiment 3
Choose following crude drug: the Radix Astragali 20 weight portion, Rhizoma Dioscoreae 10 weight portion, Cortex Cinnamomi 3 weight portion, Semen Phaseoli 3 weight portion, Poria 10 weight portion, Radix Ampelopsis 2 weight portion, the Rhizoma Atractylodis Macrocephalae 3 weight portion, to lead a cow 3 weight portions, Stigma Croci 5 weight portion, Sanguis Draxonis 3 weight portion, Radix Sophorae Flavescentis 3 weight portion in vain, Cortex Moutan 5 weight portion, Semen Coicis 5 weight portion;
Ethanol water 500 weight portion heating-condensing by medicinal for above-mentioned raw materials 90% merges medicinal liquid after refluxing 3 times each 3 hours, is drying to obtain pharmaceutical composition, is pulverized and make granule after filtrate is concentrated.
Clinical trial
The capsule that oral pharmaceutical composition of the present invention is obtained, every day 3 times, each 1.5g, January was 1 course for the treatment of;
Case 1 Lee, female, at 60 years old age, canthus and face have fragmentary macula lutea, and after taking pharmaceutical composition of the present invention obtained 2 courses for the treatment of of capsule, macula lutea disappears substantially, after consolidating for 1 course for the treatment of, without recurrence.
Case 2 Zhao, man, at 65 years old age, suffers from chronic nephritis, local edema, waist and leg ache, and after taking pharmaceutical composition of the present invention obtained 3 courses for the treatment of of capsule, edema disappears substantially, and waist and leg ache obviously alleviates, and after consolidating 2 courses for the treatment of, is almost recovered.
Case 3 Wang, female, at 55 years old age, the macula lutea of cheek skin 15% area with edema slightly, after taking pharmaceutical composition of the present invention obtained 4 courses for the treatment of of capsule, macula lutea fades away, edema extinction, and after consolidating 2 courses for the treatment of, naked eyes cannot see macula lutea.
Case 4 high so-and-so, female, at 70 years old age, the macula lutea of forehead, canthus and cheek sheet, after taking pharmaceutical composition of the present invention obtained 4 months courses for the treatment of of capsule, macula lutea area significantly reduces, and after continuing to strengthen 2 courses for the treatment of, substantially disappears.
Case 5 Liu, man, 60 years old age, waist and leg ache several years, there is interval edema in nearest trick, take the obtained capsule of pharmaceutical composition of the present invention after 2 months, the state of an illness just has largely to be alleviated, after consolidating 2 courses for the treatment of, then occur without edema phenomenon, waist and leg ache symptom disappears substantially.
As can be seen from above case, pharmaceutical composition of the present invention can have obvious therapeutical effect to age-related macular edema.Adopt natural Chinese medicines composition, without any side effects, eliminate Patient drug's fear; Cooperatively interacted by each crude drug, mutually auxiliary formation can conditioning viscera, Yin Yang balancing, soothing liver-QI gas, promoting blood circulation, change blood stasis, smooth circulation, toxin expelling element, molten mottle, increase-volume face, effectively treats age-related macular edema.
Above-described embodiment is only be described the preferred embodiment of the present invention; not scope of the present invention is limited; under not departing from the present invention and designing the prerequisite of spirit; the various distortion that those of ordinary skill in the art make technical scheme of the present invention and improvement, all should fall in protection domain that claims of the present invention determines.
Claims (5)
1. treat a pharmaceutical composition for age-related macular edema, it is characterized in that comprising following crude drug is prepared from: the Radix Astragali, Rhizoma Dioscoreae, Cortex Cinnamomi, Semen Phaseoli, Poria, Radix Ampelopsis, the Rhizoma Atractylodis Macrocephalae, lead a cow in vain, Stigma Croci, Sanguis Draxonis, Radix Sophorae Flavescentis, Cortex Moutan, Semen Coicis.
2. the pharmaceutical composition for the treatment of age-related macular edema according to claim 1, it is characterized in that described crude drug consumption is: Radix Astragali 10-20 weight portion, Rhizoma Dioscoreae 5-10 weight portion, Cortex Cinnamomi 3-5 weight portion, Semen Phaseoli 1-3 weight portion, Poria 5-10 weight portion, Radix Ampelopsis 2-5 weight portion, Rhizoma Atractylodis Macrocephalae 3-5 weight portion, to lead a cow 1-3 weight portion, Stigma Croci 3-5 weight portion, Sanguis Draxonis 1-3 weight portion, Radix Sophorae Flavescentis 3-5 weight portion in vain, Cortex Moutan 3-5 weight portion, Semen Coicis 5-10 weight portion.
3. the pharmaceutical composition for the treatment of age-related macular edema according to claim 2, it is characterized in that described crude drug consumption is: the Radix Astragali 15 weight portion, Rhizoma Dioscoreae 8 weight portion, Cortex Cinnamomi 4 weight portion, Semen Phaseoli 2 weight portion, Poria 8 weight portion, Radix Ampelopsis 3 weight portion, the Rhizoma Atractylodis Macrocephalae 4 weight portion, to lead a cow 2 weight portions, Stigma Croci 4 weight portion, Sanguis Draxonis 2 weight portion, Radix Sophorae Flavescentis 4 weight portion in vain, Cortex Moutan 4 weight portion, Semen Coicis 8 weight portion.
4. the pharmaceutical composition of the treatment age-related macular edema according to any one of claim 1-3, it is characterized in that: merge medicinal liquid by after described crude drug ethanol water heating-condensing backflow 2-4 time, be drying to obtain after filtrate is concentrated, described ethanol water concentration is 70-95%, and consumption is 5-8 times of crude drug gross weight.
5. the pharmaceutical composition for the treatment of age-related macular edema according to claim 4, it is characterized in that: described reflow's cycle is 3 times, each return time is 3 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510205634.5A CN104857365A (en) | 2015-04-27 | 2015-04-27 | Drug combination for curing senile macular oedema |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510205634.5A CN104857365A (en) | 2015-04-27 | 2015-04-27 | Drug combination for curing senile macular oedema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104857365A true CN104857365A (en) | 2015-08-26 |
Family
ID=53903827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510205634.5A Pending CN104857365A (en) | 2015-04-27 | 2015-04-27 | Drug combination for curing senile macular oedema |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104857365A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1113753A (en) * | 1994-06-17 | 1995-12-27 | 殷广全 | Spot curing and beautifying preparation |
| CN103006979A (en) * | 2012-11-23 | 2013-04-03 | 王先忠 | Chinese medicinal composition for treating nephrotic edema |
| CN103585404A (en) * | 2013-08-19 | 2014-02-19 | 郝振荣 | Empirical prescription for treating dropsy |
-
2015
- 2015-04-27 CN CN201510205634.5A patent/CN104857365A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1113753A (en) * | 1994-06-17 | 1995-12-27 | 殷广全 | Spot curing and beautifying preparation |
| CN103006979A (en) * | 2012-11-23 | 2013-04-03 | 王先忠 | Chinese medicinal composition for treating nephrotic edema |
| CN103585404A (en) * | 2013-08-19 | 2014-02-19 | 郝振荣 | Empirical prescription for treating dropsy |
Non-Patent Citations (1)
| Title |
|---|
| 尹智功等: "益脾肾法、清利法与益脾肾清利法治疗慢性肾功能衰竭的比较研究", 《湖北中医杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105169133B (en) | Treat the Chinese medicine preparation of psoriasis | |
| CN102293900B (en) | Chinese medicine for treating infantile diarrhea | |
| CN103520616B (en) | Traditional Chinese medicine for treating kidney-yin deficiency type frequent micturition | |
| CN101361919B (en) | Traditional Chinese medicine preparation for treating various skin pyogenic infection, inflammation, trauma | |
| CN104027517A (en) | Traditional Chinese medicine for treating acute enteritis | |
| CN105963649A (en) | Traditional Chinese medicine for treating stomach diseases | |
| CN101366903B (en) | Traditional Chinese medicine composition for treating climacteric syndrome | |
| CN104027461A (en) | Traditional Chinese medicine composition for treating urticaria | |
| CN103893502A (en) | Traditional Chinese medicine for treating phlyctenular conjunctivitis | |
| CN103656013A (en) | Traditional Chinese medicine for treating gastrointestinal hypofunction after abdominal operations and preparation method of traditional Chinese medicine | |
| CN1385191A (en) | Medicine for treating liver disease | |
| CN103127351A (en) | Traditional Chinese medicine for treating premature menstruation | |
| CN104857365A (en) | Drug combination for curing senile macular oedema | |
| CN103316283B (en) | Traditional Chinese medicinal composition for treating chronic cholecystitis, and preparation method thereof | |
| CN101979035A (en) | Medicament for treating gynecological abnormal leucorrhea | |
| CN106334152A (en) | Traditional Chinese medicine formula for treating acute hepatitis | |
| CN104352841A (en) | Traditional Chinese medicine composition for treating pediatric night sweat and preparation method thereof | |
| CN103550736B (en) | Traditional Chinese medicine for treating blood stasis and channel blockage symptom type amenorrhea | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN105983011A (en) | Traditional Chinese medicine composition for treating dysmenorrhea | |
| CN106177686A (en) | A kind of Chinese medicine for treating urticaria | |
| CN105169341A (en) | Traditional Chinese medicine composition for treating qi stagnation | |
| CN106309887A (en) | Traditional Chinese medicine preparation for treating neurasthenia | |
| CN103623348A (en) | Traditional Chinese medicine composition for treating stomach cancer | |
| CN104324334A (en) | Traditional Chinese medicine for treating hyperthyroidism and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150826 |
|
| RJ01 | Rejection of invention patent application after publication |